Boehringer’s Mycoplasma hyopneumonia vaccine hits milestone

30-09-2013 | | |
Boehringer’s Mycoplasma hyopneumonia vaccine hits milestone

The pharmaceutical company Boehringer Ingelheim has announced a milestone in the use of Ingelvac MycoFlex vaccine against Mycoplasma hyopneumonia – the vaccination of 500 million pigs worldwide.

The vaccine was launched by Boehringer Ingelheim in the Americas, Asia and Europe in 2008. The vaccination is used for the treatment of weaned piglets to reduce lung lesions following infection with Mycoplasma hyopneumoniae.

“The number of doses of Ingelvac MycoFlex that we sold since the vaccine’s launch in 2008 shows that at least 500 million pigs have now been protected by its use. Reaching this landmark in preventing diseases makes us proud,” comments George Heidgerken, Senior Vice President of Animal Health at Boehringer Ingelheim.

Innovation in bottle design

A recent innovation in bottle design provides veterinarians and pig producers with a simple and practical way to mix Ingelvac MycoFlex and Ingelvac CircoFlex vaccines for their simultaneous application. Originally inspired by customer demand, the design allows the two pig vaccines to be mixed together directly in the MycoFlex Headspace bottle – thus eliminating the need for an additional mixing vessel.

Europe-wide market research has revealed that more than 86% of veterinarians who vaccinate their pigs against PCV2 (porcine circovirus type 2) and M. hyo. (Mycoplasma hyopneumoniae) are using that option2.

The Flexcombo concept of the mixable stand-alone vaccines is the first and only solution to protect pigs against both PCV2 and M. hyo. with a single shot around weaning.

As well as providing premium protection, this single-shot injection of the vaccine mix reduces stress for the pigs and thus brings an additional benefit in animal welfare.

2: Market research “Produkt+Markt” Germany, Denmark, Spain, France, Netherlands, UK, Italy, 2012 (data on file).